Margo
Georgiadis

Margo Georgiadis is building a drug company on a simple and deeply strange bet: humans have spent 10,000 years eating, drinking, and ingesting natural compounds - turmeric, herbs, foods, supplements - and surviving. That's 10,000 years of unintentional safety testing. The question CONECTA AI asks is: which of those compounds, already cleared by human biology, could be optimized into precision medicines?

The answer, if Montai Therapeutics is right, could reshape how chronic disease gets treated. Not with expensive biologics administered by infusion, but with small-molecule pills derived from chemistry nature already invented. Pfizer thinks this line of thinking is worth $700 million.

Georgiadis arrived at Flagship Pioneering - the Cambridge, Massachusetts venture creation studio that spawned Moderna - with a resume that doesn't look like any biotech founder's. She ran Google's commercial operations across an entire hemisphere. She led Mattel through a digital transformation. She took Ancestry.com from a genealogy hobbyist platform to a genomics giant with 20 million DNA profiles and then watched it sell to Blackstone for five billion dollars. Five industries. One thread: she finds data-rich problems at inflection points and figures out how to run through them.

Georgiadis grew up in Chicago, the daughter of Greek-American parents who gave her a surname and a stubborn belief that operational excellence is itself a form of creativity. She went to Harvard twice - earning her economics degree magna cum laude with Phi Beta Kappa honors, then returning for an MBA four years later. She graduated as a Baker Scholar, placing in the top five percent of her class. Then she went back to McKinsey, where she had started, and eventually made partner.

The move to Discover Financial in 2004 was the first of several pivots that look, in hindsight, like a calculated curriculum. At Discover, she ran card products and marketing, then led the company through its IPO. At Google, starting in 2009, she built and scaled commercial infrastructure across the Americas - nine years that coincided with Google's transformation from search company to advertising behemoth. In between, she joined Groupon as COO for five months during its IPO filing before returning to Google. She has described the Groupon departure as one of the hardest professional decisions she ever made.

Mattel came in 2017. The toy giant needed digital transformation - an unglamorous mandate at a company famous for Barbie and Hot Wheels. She took it. Then came Ancestry, where the data challenge was genomic: 10 million DNA profiles that she doubled to 20 million while pushing subscription revenue past $1 billion annually. The $5 billion Blackstone acquisition closed under her leadership in 2020.

Georgiadis has said it plainly: as you become more senior, it gets harder to receive honest feedback. The people around you have incentives to soften the truth. Her solution, built deliberately over more than a decade, is a diverse advisory network assembled not for comfort but for candor - people who will "speak truth to power."

She describes great advisors as serving three specific functions: helping you see the problem from multiple angles, helping you balance short-term urgency against long-term priorities, and asking the questions you need to hear even when you don't want to. This is not a platitude. It's a structural approach to the information deficit that accumulates at the top of organizations.

At each of her CEO stints - Mattel, Ancestry, Montai - she has demonstrated a pattern: arrive at a company facing an inflection point, rebuild the data infrastructure that determines how decisions get made, and then execute through the uncertainty that follows. The industry changes. The playbook doesn't.